Teladoc (TDOC) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Teladoc (NYSE:TDOC) have received a consensus recommendation of “Buy” from the twenty analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $43.00.

TDOC has been the topic of several research reports. Jefferies Group initiated coverage on Teladoc in a report on Friday, January 26th. They set a “buy” rating and a $40.00 price objective on the stock. Canaccord Genuity lifted their price target on Teladoc from $42.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. ValuEngine upgraded Teladoc from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Cantor Fitzgerald reiterated a “hold” rating and issued a $35.00 price target (up from $31.00) on shares of Teladoc in a report on Tuesday, February 27th. Finally, Chardan Capital reiterated a “buy” rating and issued a $47.00 price target (down from $48.00) on shares of Teladoc in a report on Wednesday, February 28th.

In related news, insider Adam C. Vandervoort sold 27,809 shares of the business’s stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $38.62, for a total transaction of $1,073,983.58. Following the transaction, the insider now directly owns 19,338 shares in the company, valued at approximately $746,833.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Jason N. Gorevic sold 40,000 shares of the business’s stock in a transaction on Monday, March 12th. The stock was sold at an average price of $43.27, for a total value of $1,730,800.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 483,954 shares of company stock worth $19,960,682. 3.95% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in TDOC. California Public Employees Retirement System grew its stake in Teladoc by 52.1% during the 3rd quarter. California Public Employees Retirement System now owns 11,409 shares of the health services provider’s stock worth $378,000 after buying an additional 3,909 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in Teladoc by 12.6% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 249,789 shares of the health services provider’s stock worth $8,706,000 after acquiring an additional 28,038 shares during the period. Strs Ohio lifted its position in Teladoc by 33.3% during the 4th quarter. Strs Ohio now owns 304,226 shares of the health services provider’s stock worth $10,602,000 after acquiring an additional 76,057 shares during the period. SG Americas Securities LLC acquired a new stake in Teladoc during the 4th quarter worth about $101,000. Finally, Riverbridge Partners LLC lifted its position in Teladoc by 44.1% during the 4th quarter. Riverbridge Partners LLC now owns 859,018 shares of the health services provider’s stock worth $29,937,000 after acquiring an additional 262,959 shares during the period.

Teladoc traded up $0.65, hitting $49.35, during trading on Monday, according to MarketBeat Ratings. 755,793 shares of the stock were exchanged, compared to its average volume of 1,145,645. The company has a market capitalization of $3.04 billion, a P/E ratio of -29.91 and a beta of 0.35. Teladoc has a 1 year low of $27.30 and a 1 year high of $49.85. The company has a quick ratio of 4.15, a current ratio of 4.15 and a debt-to-equity ratio of 0.38.

Teladoc (NYSE:TDOC) last released its quarterly earnings data on Tuesday, May 1st. The health services provider reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.04. The company had revenue of $89.64 million for the quarter, compared to the consensus estimate of $86.77 million. Teladoc had a negative return on equity of 20.40% and a negative net margin of 41.06%. Teladoc’s quarterly revenue was up 109.0% on a year-over-year basis. During the same period last year, the business posted ($0.30) EPS. equities analysts anticipate that Teladoc will post -1.37 earnings per share for the current year.

Teladoc Company Profile

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply